ACEL vs BABA

ACEL's deterministic health score is concerning with a Piotroski F-Score of 4/9, indicating marginal financial stability. While the company shows strong earnings growth and beats earnings estimates consistently, high leverage (Debt/Equity: 2.22) and weak insider sentiment counterbalance these positives. Valuation is mixed—trading below analyst target of $15.17 but above the conservative Graham Number of $5.93. The stock faces headwinds from recent price underperformance and insider selling, despite solid ROE and revenue momentum.

The Advanced Deterministic Scorecard reveals a mixed financial profile for Alibaba (BABA), with a weak Piotroski F-Score of 4/9 indicating suboptimal financial health, and no available Altman Z-Score limiting distress risk assessment. While valuation metrics appear favorable relative to peers—especially a Price/Sales of 0.41 and Forward P/E of 19.50—earnings growth is sharply negative (YoY EPS down 71%), and recent quarterly beats have reversed into consistent misses over the last four quarters. Strong insider sentiment and a bullish analyst consensus (strong_buy) contrast with deteriorating profitability and weak technical trends (10/100). The stock trades significantly above the Graham Number ($102.68) and intrinsic value estimate ($51.38), suggesting overvaluation unless growth rebounds materially.